1 of 3
FEATURED COMPANIES
- Amgen Inc.
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
- Heron Therapeutics, Inc.
- Merck & Co.
- NOVARTIS AG
- MORE
The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per this report. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.
Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.
G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.
Further key findings from the report suggest:
Please note: This product will be delivered within 48 business hours after receipt of order.
Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.
G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.
Further key findings from the report suggest:
- Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share
- By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen
- North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period
- Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives
- Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile
Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Amgen Inc.
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
- Heron Therapeutics, Inc.
- Merck & Co.
- NOVARTIS AG
- MORE
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.2 Research Methodology
1.3 Research Scope and Assumptions
1.4 List to Data Sources
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/ Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage
3.4 Clinical Profiles of Disruptive Drugs
3.5 Regulatory Framework
3.6 Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
3.6.1.2 Large number of side effects associated with the cancer treatment
3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
3.6.2 Market Restraint Analysis
3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
3.6.2.2 Unmet needs in cancer supportive care
3.6.2.3 Safety issues associated with supportive care agents
3.7 Patent Expiry Analysis
3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
3.8.1 Industry Analysis - Porter's
3.8.2 major deals & strategic alliances analysis
3.8.2.1 Joint Ventures
3.8.2.2 Mergers & Acquisitions
3.8.2.3 Licensing & Partnership
3.8.2.4 technology collaborations
3.8.3 MARKET Dynamics and Brand STRATEGIES
Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 - 2026 (USD Million)
4.1 Definitions & Scope
4.2 Drug Class Market Share Analysis, 2018 & 2026
4.3 Segment Dashboard
4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
4.4.1 G-CSFs
4.4.1.1 G-CSFs market, 2015 - 2026 (USD Million)
4.4.2 Erythropoietin Stimulating Agents (ESA)
4.4.2.1 Erythropoietin Stimulating Agents market, 2015 - 2026 (USD Million)
4.4.3 Antiemetics
4.4.3.1 Antiemetics market, 2015 - 2026 (USD Million)
4.4.4 Bisphosphonates
4.4.4.1 Bisphosphonates market, 2015 - 2026 (USD Million)
4.4.5 Opioids
4.4.5.1 opioids market, 2015 - 2026 (USD Million)
4.4.6 NSAIDs and Others
4.4.6.1 NSAIDs and Others market, 2015 - 2026 (USD Million)
Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis
5.1 Regional Market Share Analysis, 2018 & 2026
5.2 Regional Market Dashboard
5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1 North America
5.3.2 Europe
5.3.3 Asia pacific
5.3.4 Latin America
5.3.5 Middle east & Africa
5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
5.5 North America
5.5.1 North America cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.1.1 U.S.
5.5.1.2 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.1.3 Canada
5.5.1.4 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.1 U.K.
5.5.2.2 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.3 Germany
5.5.2.4 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.5 France
5.5.2.6 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.7 Italy
5.5.2.8 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.9 Spain
5.5.2.10 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.1 CHINA
5.5.3.2 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.3 India
5.5.3.4 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.5 Japan
5.5.3.6 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.7 Thailand
5.5.3.8 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.9 South Korea
5.5.3.10 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.1 Brazil
5.5.4.2 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.3 Mexico
5.5.4.4 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.5 Argentina
5.5.4.6 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.7 Colombia
5.5.4.8 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.1 South Africa
5.5.5.2 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.3 Saudi Arabia
5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.5 UAE
5.5.5.6 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
Chapter 6 Cancer Supportive Care Drugs Market - Competitive Analysis
6.1 Recent Developments & Impact analysis, by key market participants
6.2 Company Categorization
6.2.1 Market Leader
6.2.2 Key innovators
6.2.3 Emerging Players
6.2.3.1 Pfizer (Hospira)
6.2.3.2 Heron Therapeutics
6.2.3.3 Spectrum Pharmaceuticals
6.2.3.4 Myelo Therapeutics
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company market share analysis, 2018
6.4 Key Companies Profiled
6.4.1 Amgen Inc.
6.4.1.1 Company overview
6.4.1.2 Financial Performance
6.4.1.3 product benchmarking
6.4.1.4 recent developments
6.4.2 Merck & Co.
6.4.2.1 Company Overview
6.4.2.2 Financial Performance
6.4.2.3 Product benchmarking
6.4.2.4 Recent developments
6.4.3 Johnson & Johnson Services, Inc.
6.4.3.1 Company Overview
6.4.3.2 Financial Performance
6.4.3.3 Product benchmarking
6.4.3.4 Recent developments
6.4.4 Heron Therapeutics, Inc.
6.4.4.1 Company Overview
6.4.4.2 Financial Performance
6.4.4.3 Product benchmarking
6.4.4.4 Recent developments
6.4.5 NOVARTIS AG
6.4.5.1 Company Overview
6.4.5.2 Financial Performance
6.4.5.3 Product benchmarking
6.4.5.4 Recent developments
6.4.6 TESARO, Inc.
6.4.6.1 Company Overview
6.4.6.2 Financial Performance
6.4.6.3 Product benchmarking
6.4.6.4 Recent developments
6.4.7 F. Hoffmann-La Roche AG
6.4.7.1 Company Overview
6.4.7.2 Financial Performance
6.4.7.3 Product benchmarking
6.4.7.4 Recent developments
6.4.8 HELSINN Healthcare SA
6.4.8.1 Company Overview
6.4.8.2 Product benchmarking
6.4.8.3 Recent developments
1.1 Market Segmentation
1.2 Research Methodology
1.3 Research Scope and Assumptions
1.4 List to Data Sources
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/ Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage
3.4 Clinical Profiles of Disruptive Drugs
3.5 Regulatory Framework
3.6 Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
3.6.1.2 Large number of side effects associated with the cancer treatment
3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
3.6.2 Market Restraint Analysis
3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
3.6.2.2 Unmet needs in cancer supportive care
3.6.2.3 Safety issues associated with supportive care agents
3.7 Patent Expiry Analysis
3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
3.8.1 Industry Analysis - Porter's
3.8.2 major deals & strategic alliances analysis
3.8.2.1 Joint Ventures
3.8.2.2 Mergers & Acquisitions
3.8.2.3 Licensing & Partnership
3.8.2.4 technology collaborations
3.8.3 MARKET Dynamics and Brand STRATEGIES
Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 - 2026 (USD Million)
4.1 Definitions & Scope
4.2 Drug Class Market Share Analysis, 2018 & 2026
4.3 Segment Dashboard
4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
4.4.1 G-CSFs
4.4.1.1 G-CSFs market, 2015 - 2026 (USD Million)
4.4.2 Erythropoietin Stimulating Agents (ESA)
4.4.2.1 Erythropoietin Stimulating Agents market, 2015 - 2026 (USD Million)
4.4.3 Antiemetics
4.4.3.1 Antiemetics market, 2015 - 2026 (USD Million)
4.4.4 Bisphosphonates
4.4.4.1 Bisphosphonates market, 2015 - 2026 (USD Million)
4.4.5 Opioids
4.4.5.1 opioids market, 2015 - 2026 (USD Million)
4.4.6 NSAIDs and Others
4.4.6.1 NSAIDs and Others market, 2015 - 2026 (USD Million)
Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis
5.1 Regional Market Share Analysis, 2018 & 2026
5.2 Regional Market Dashboard
5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.3.1 North America
5.3.2 Europe
5.3.3 Asia pacific
5.3.4 Latin America
5.3.5 Middle east & Africa
5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
5.5 North America
5.5.1 North America cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.1.1 U.S.
5.5.1.2 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.1.3 Canada
5.5.1.4 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.1 U.K.
5.5.2.2 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.3 Germany
5.5.2.4 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.5 France
5.5.2.6 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.7 Italy
5.5.2.8 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.2.9 Spain
5.5.2.10 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.1 CHINA
5.5.3.2 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.3 India
5.5.3.4 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.5 Japan
5.5.3.6 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.7 Thailand
5.5.3.8 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.3.9 South Korea
5.5.3.10 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.1 Brazil
5.5.4.2 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.3 Mexico
5.5.4.4 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.5 Argentina
5.5.4.6 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.4.7 Colombia
5.5.4.8 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.1 South Africa
5.5.5.2 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.3 Saudi Arabia
5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
5.5.5.5 UAE
5.5.5.6 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
Chapter 6 Cancer Supportive Care Drugs Market - Competitive Analysis
6.1 Recent Developments & Impact analysis, by key market participants
6.2 Company Categorization
6.2.1 Market Leader
6.2.2 Key innovators
6.2.3 Emerging Players
6.2.3.1 Pfizer (Hospira)
6.2.3.2 Heron Therapeutics
6.2.3.3 Spectrum Pharmaceuticals
6.2.3.4 Myelo Therapeutics
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company market share analysis, 2018
6.4 Key Companies Profiled
6.4.1 Amgen Inc.
6.4.1.1 Company overview
6.4.1.2 Financial Performance
6.4.1.3 product benchmarking
6.4.1.4 recent developments
6.4.2 Merck & Co.
6.4.2.1 Company Overview
6.4.2.2 Financial Performance
6.4.2.3 Product benchmarking
6.4.2.4 Recent developments
6.4.3 Johnson & Johnson Services, Inc.
6.4.3.1 Company Overview
6.4.3.2 Financial Performance
6.4.3.3 Product benchmarking
6.4.3.4 Recent developments
6.4.4 Heron Therapeutics, Inc.
6.4.4.1 Company Overview
6.4.4.2 Financial Performance
6.4.4.3 Product benchmarking
6.4.4.4 Recent developments
6.4.5 NOVARTIS AG
6.4.5.1 Company Overview
6.4.5.2 Financial Performance
6.4.5.3 Product benchmarking
6.4.5.4 Recent developments
6.4.6 TESARO, Inc.
6.4.6.1 Company Overview
6.4.6.2 Financial Performance
6.4.6.3 Product benchmarking
6.4.6.4 Recent developments
6.4.7 F. Hoffmann-La Roche AG
6.4.7.1 Company Overview
6.4.7.2 Financial Performance
6.4.7.3 Product benchmarking
6.4.7.4 Recent developments
6.4.8 HELSINN Healthcare SA
6.4.8.1 Company Overview
6.4.8.2 Product benchmarking
6.4.8.3 Recent developments
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Amgen Inc.
- Merck & Co.
- Johnson & Johnson SeRvices, Inc.
- Heron Therapeutics, Inc.
- NOVARTIS AG
- TESARO, Inc.
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
Note: Product cover images may vary from those shown
